SYRS stock forecast
Our latest prediction for Syros Pharmaceuticals, Inc.'s stock price was made on the July 17, 2019 when the stock price was at 7.59$.
In the short term (2weeks), SYRS's stock price should underperform the market by -1.58%. During that period the price should oscillate between -11.69% and +12.29%.
In the medium term (3months), SYRS's stock price should underperform the market by -0.05%. During that period the price should oscillate between -25.39% and +33.49%.Get email alerts
About Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
At the moment the company generates 2M USD in revenues.
On its last earning announcement, the company reported a loss of -1.96$ per share.
The book value per share is 3.23$
Three months stock forecastJuly 17, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|